Table 4 Predictor studies eligible for pooled analysis about adjusted HRs
Study ID | Country | Imaging examination method | Definition of disease | Trail Group | Control Group | Follow-up years | Primary endpoints | HR estimate | HR | 95%CI | P value | NOS score | K value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | NO.of Hypoenhancement at arterial phase | NO.of Hyperenhancement at arterial phase | Â | Â | Â | Â | Â | Â | Â | Â |
Zhang 2020 [34] | China | MRI | ICC | 40 | 28 | 4.7 | OS | paper | 1.878 | 1.063–3.320 | 0.030 | 8 | 0.83 |
Teraoku 2020 [21] | Japan | CT | IMCC | 32 | 8 | 7.0 | OS | paper | 6.680 | 1.160–128.300 | 0.030 | 7 | NA |
Kim 2011 [18] | Korea | CT | IMCC | 49 | 15 | 5.5 | EFS | paper | 3.011 | 1.252–7.238 | 0.014 | 7 | NA |
Fujita 2017 [29] | Japan | CT | IMCC | 13 | 34 | 11.0 | EFS | paper | 5.853 | 2.069–17.399 |  < 0.001 | 8 | NA |
Ariizumi 2011 [20] | Japan | CT | IMCC | 109 | 25 | 15.0 | OS | paper | 2.740 | NA | 0.045 | 8 | NA |
| Â | Â | Â | Â | NO. of Infiltrative tumor margin | NO. of absence | Â | Â | Â | Â | Â | Â | Â | Â |
Kim 2019 [31] | Korea | MRI | IMCC | NA | NA | 8.0 | EFS | paper | 2.130 | 0.890–5.110 | 0.090 | 8 | NA |
Jiang 2011 [25] | China | CT or MRI | ICC | 151 | 193 | 10.0 | OS | paper | 2.234 | 1.659–3.009 |  < 0.001 | 8 | NA |
Park 2021 [30] | Korea | CT | IMCC | 27 | 206 | 4.8 | EFS | paper | 1.630 | 1.030–2.590 | 0.040 | 7 | 0.99 |
This study | China | CT | ICC | 85 | 76 | 15.0 | OS | paper | 2.565 | 1.633–4.029 |  < 0.001 | 8 | NA |
EFS | paper | 2.252 | 1.478–3.432 |  < 0.001 | |||||||||
Rhee 2022 [24] | Korea | MRI | IMCC | 32 | 176 | 8.0 | OS | paper | NA | NA | NA | 8 | NA |
| Â | Â | Â | Â | NO. of Bile duct invasion | NO. of absence | Â | Â | Â | Â | Â | Â | Â | Â |
Kim 2019 [31] | Korea | MRI | IMCC | 33 | 21 | 8.0 | OS | paper | 2.040 | 0.770–5.40 | 0.151 | 8 | NA |
EFS | paper | 2.170 | 0.860–5.460 | 0.101 | |||||||||
Rhee 2022 [24] | Korea | MRI | IMCC | 116 | 92 | 8.0 | OS | paper | 1.886 | 1.271–2.799 | 0.002 | 8 | NA |
This study | China | CT | ICC | 87 | 74 | 15.0 | OS | paper | 1.186 | 0.757–1.860 | 0.457 | 8 | NA |
Min 2019 [22] | Korea | MRI | IMCC | 54 | 80 | 8.0 | OS | paper | NA | NA | NA | 8 | 0.75–0.95 |
EFS | paper | NA | NA | NA | |||||||||
Jin 2022 [40] | China | MRI | IMCC | 69 | 162 | 7.8 | OS | paper | NA | NA | NA | 8 | NA |
EFS | paper | NA | NA | NA | |||||||||
Park 2021 [30] | Korea | CT | IMCC | 112 | 121 | 4.8 | EFS | paper | NA | NA | NA | 7 | 0.99 |
| Â | Â | Â | Â | NO. of Necrosis sign | NO. of absence | Â | Â | Â | Â | Â | Â | Â | Â |
Aherne 2018 [35] | USA | CT | ICC | 25 | 41 | 8.0 | OS | paper | 3.180 | 1.290–7.860 | 0.012 | 7 | NA |
EFS | paper | 1.950 | 1.070–3.540 | 0.060 | NA | ||||||||
Min 2019 [22] | Korea | MRI | IMCC | 77 | 57 | 8.0 | OS | paper | NA | NA | NA | 8 | 0.75–0.95 |
EFS | paper | NA | NA | NA | |||||||||
Jin 2022 [40] | China | MRI | IMCC | 145 | 86 | 7.8 | OS | paper | NA | NA | NA | 8 | NA |
EFS | paper | NA | NA | NA | NA | ||||||||
| Â | Â | Â | Â | NO. of perihilar tumor location | NO. of peripheral tumor location | Â | Â | Â | Â | Â | Â | Â | Â |
Jiang 2011 [25] | China | CT or MRI | ICC | 37 | 307 | 10.0 | OS | paper | 1.162 | 0.711–1.899 | 0.549 | 8 | NA |
Jin 2022 [40] | China | MRI | IMCC | 102 | 129 | 7.8 | OS | paper | NA | NA | NA | 8 | NA |
EFS | paper | NA | NA | NA | |||||||||
Rhee 2022 [24] | Korea | MRI | IMCC | 66 | 142 | 8.0 | OS | paper | NA | NA | NA | 8 | NA |
|  |  |  |  | NO. of The area of DWI Diffusion restriction accounted for the tumor area < 1/3 | NO. of The area of DWI Diffusion restriction accounted for the tumor area > 1/3 |  |  |  |  |  |  |  |  |
Promsorn 2022 [33] | Thailand | MRI | IMCC | 29 | 44 | 5.0 | OS | paper | 2.039 | 1.180–3.535 | 0.011 | 8 | NA |
Lee 2016 [26] | Korea | MRI | IMCC | 43 | 48 | 5.0 | OS | paper | 2.660 | NA | 0.024 | 8 | NA |
| Â | Â | Â | Â | NO.of Intermediate group | NO.of Hypointense group | Â | Â | Â | Â | Â | Â | Â | Â |
Koh 2016 [17] | Korea | MRI | IMCC | 21 | 18 | 5.0 | OS | paper | NA | NA | NA | 8 | NA |
EFS | paper | 5.000 | 1.629–20.352 | 0.012 | |||||||||
Min 2019 [22] | Korea | MRI | IMCC | 8 | 126 | 8.0 | OS | paper | NA | NA | NA | 8 | 0.75–0.95 |
EFS | paper | NA | NA | NA | |||||||||
| Â | Â | Â | Â | NO. of Peritumoral arterial hyperenhancement | NO. of absence | Â | Â | Â | Â | Â | Â | Â | Â |
Min 2019 [22] | Korea | MRI | IMCC | 39 | 95 | 8.0 | OS | paper | NA | NA | NA | 8 | 0.75–0.95 |
EFS | paper | NA | NA | NA | |||||||||
Rhee 2022 [24] | Korea | MRI | IMCC | 116 | 92 | 8.0 | OS | paper | NA | NA | NA | 8 | NA |